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Recent epidemics demonstrate the global threat of Zika virus
(ZIKV), a flavivirus transmitted by mosquitoes. Although infection
is usually asymptomatic or mild, newborns of infected mothers can
display severe symptoms, including neurodevelopmental abnor-
malities and microcephaly. Given the large-scale spread, symptom
severity, and lack of treatment or prophylaxis, a safe and effective
ZIKV vaccine is urgently needed. However, vaccine design is com-
plicated by concern that elicited antibodies (Abs) may cross-react
with other flaviviruses that share a similar envelope protein, such
as dengue virus, West Nile virus, and yellow fever virus. This cross-
reactivity may worsen symptoms of a subsequent infection
through Ab-dependent enhancement. To better understand the
neutralizing Ab response and risk of Ab-dependent enhancement,
further information on germline Ab binding to ZIKV and the mat-
uration process that gives rise to potently neutralizing Abs is
needed. Here we use binding and structural studies to compare
mature and inferred-germline Ab binding to envelope protein do-
main III of ZIKV and other flaviviruses. We show that affinity mat-
uration of the light-chain variable domain is important for strong
binding of the recurrent VH3-23/VK1-5 neutralizing Abs to ZIKV
envelope protein domain III, and identify interacting residues that
contribute to weak, cross-reactive binding to West Nile virus.
These findings provide insight into the affinity maturation process
and potential cross-reactivity of VH3-23/VK1-5 neutralizing Abs,
informing precautions for protein-based vaccines designed to elicit
germline versions of neutralizing Abs.
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Zika virus (ZIKV) is an arthropod-borne flavivirus first dis-covered in 1947, with the first reported human case in 1964
and large outbreaks in 2007 and 2013 to 2015 (1–8). Although
commonly transmitted by mosquitoes, ZIKV can also be trans-
mitted sexually and can persist in infected individuals for up to
several months (9–12). Infection is either asymptomatic or cau-
ses mild symptoms, including fever, conjunctivitis, headache,
rash, and arthralgia in ∼20% of cases, and severe neurologic
problems, such as meningoencephalitis or Guillain-Barré syn-
drome, in rare cases (4, 13–15). There are major concerns about
ZIKV infection during pregnancy, which can cause fetal neuro-
developmental abnormalities, such as microcephaly (10, 16–19).
Given the large-scale spread, symptom severity, and lack of
treatment or prophylaxis, a safe and effective ZIKV vaccine is
urgently needed.
The ZIKV envelope (E) protein—containing envelope protein
domain (ED)I, EDII, and EDIII—is similar to the E protein of
other flaviviruses, including dengue virus serotypes 1 to 4
(DENV1-4), West Nile virus (WNV), and yellow fever virus
(YFV) (20–22). EDIII is an important target for neutralizing
antibodies (Abs) (23–25). Indeed, many Abs against the ZIKV
EDIII domain are strongly neutralizing and are an important
component of the response to infection (26–38). A set of re-
current Abs (commonly occurring in multiple individuals, also
referred to as “public Abs”) identified from a large cohort of
patients in Brazil and Mexico potently neutralize both ZIKV and
DENV1 by binding the lateral ridge of the EDIII domain (28).
These Abs share the germline variable heavy (VH) gene segment
VH3-23 and the germline variable κ (VK) gene segment VK1-5.
One of these VH3-23/VK1-5 Abs, Z004, exhibited protection
against ZIKV infection in mice, and when used in combination with
another Ab, Z021, reduced viremia and prevented the emergence
of ZIKV escape mutations in infected macaques (28, 29).
Strongly neutralizing anti-ZIKV Abs that are derived from
known germline Ab precursors represent a potential target for a
germline-targeting approach to vaccine design. Such approaches
rely on the Ab response to an antigen being initiated through
antigen binding to a B cell receptor in its germline configuration,
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triggering B cell activation and subsequent affinity maturation
through the process of somatic hypermutation (39). However, a
potential concern for vaccine design efforts targeting the epitope
for VH3-23/VK1-5 Abs or other flavivirus epitopes is that gen-
eration of weakly neutralizing or nonneutralizing Abs against
ZIKV that cross-react with different flaviviruses could result in
enhanced infection through the process of Ab-dependent en-
hancement (ADE) (22, 40–44). It is thought that ADE can result
when the binding of cross-reactive—but non- or only poorly
neutralizing—Abs promote viral entry into Fcγ receptor (FcγR)-
expressing cells, thereby providing an alternative route of in-
fection and causing increased virus production and symptom
severity (22, 41, 42, 45–48). Therefore, understanding the ability
of germline Abs to bind flavivirus envelope proteins and mature
into specific, potently neutralizing Abs is important for devel-
opment of a safe vaccine.
The Ab affinity maturation process for EDIII recognition can
be investigated by structural comparisons of germline and ma-
ture Ab recognition of antigen. This approach provided insights
into the affinity maturation of Abs against other viruses, in-
cluding an increased understanding of modes of binding and
somatic hypermutation in broadly neutralizing Abs against HIV-
1 (49–53). In the case of ZIKV, knowledge of how both germline
and mature versions of potently neutralizing Abs bind flavivi-
ruses may enhance our understanding of the interactions that
give rise to potent neutralization versus weak cross-reactivity that
could contribute to risk for ADE.
Here we report binding and structural studies to gain insight
into affinity maturation and cross-reactivity of the VH3-23/VK1-
5 class of anti-ZIKV Abs. Through sequence alignments, surface
plasmon resonance (SPR), neutralization assays, ADE assays, and
structural studies, we compared mature and inferred germline
(iGL) Ab binding to flavivirus EDIII domains from ZIKV,
DENV1-4, WNV, and YFV. As part of this analysis, we compared
two crystal structures, an iGL Ab bound to ZIKV EDIII and a
cross-reactive mature Ab bound to WNV EDIII, with two pre-
viously determined crystal structures of potently neutralizing ma-
ture Abs bound to ZIKV and DENV1 EDIII (28). These findings
revealed components of germline maturation, including contri-
butions of somatic hypermutation in the variable domain (VL) of
the Fab, important for development of VH3-23/VK1-5 Abs that
potently neutralize ZIKV and inform cross-reactivity precautions
for flavivirus vaccine design and passive delivery of ZIKV Abs.
Results
Selection of Anti-ZIKV Abs for Binding and Structural Studies. Potent
neutralizing and recurring VH3-23/VK1-5 Abs against ZIKV
and DENV1 were previously identified in multiple donors ex-
posed to ZIKV in Mexico and Brazil (28). To investigate
germline Ab maturation and cross-reactivity of VH3-23/VK1-5
Abs, we selected a set of seven Abs identified from the memory
B cells of three of the donors: Z004mature from donor MEX 18;
Z006mature from donor MEX 105; and Z031mature, Z032mature,
Z034mature, Z035mature, and Z036mature from donor BRA 112 (SI
Appendix, Figs. S1–S3). Since crystal structures were previously
determined for Z004mature and Z006mature Fabs complexed with
DENV1 EDIII and ZIKV EDIII, respectively (PDB ID codes
5VIC and 5VIG), these Abs were of particular interest for
comparison to germline versions (28). Additionally, Z031mature,
Z032mature, Z034mature, Z035mature, and Z036mature—which we
term the Z03Xmature series—were selected since VH3-23/VK1-5
Abs from patient BRA 112 were previously shown to neutralize
ZIKV, but no structural information on EDIII recognition was
known (28).
Design of iGL Versions of Anti-ZIKV Abs.Z004iGL and Z03XiGL were
constructed based on the germline gene assignments of mature
VH3-23/VK1-5 Abs identified from donors MEX 18 and BRA
112 (SI Appendix, Figs. S1–S3) (28, 54). There are 16 amino acid
differences in the VH and 9 differences in the VL of the
Z004mature and Z004iGL sequences (Fig. 1), some occurring in
complementarity determining regions (CDRs; 3 in CDR1, 6 in
CDR2, and 5 in CDR3) (Fig. 1A). Amino acid differences be-
tween the Z03Xmature series and the Z03XiGL ranged from 13 to
23 for VH and 8 to 11 for VL (Fig. 1B). The Z03XiGL VH CDR1
(CDRH1) differed from all Z03Xmature sequences except
Z035mature, and the VL CDR1 (CDRL1) differed from all
Z03Xmature sequences except Z031mature. The Z03XiGL CDRH2
differed from all Z03Xmature sequences by at least three amino
acids, and CDRL2 was the same as all Z03Xmature sequences
except Z034mature. The CDR3s of the Z03XiGL VH and VL dif-
fered by at least two amino acids from all Z03Xmature sequences.
Assessing Binding of Anti-ZIKV IgGs with Flavivirus EDIIIs. To in-
vestigate whether iGL versions of Abs bind ZIKV EDIIIs and
whether any of the mature anti-ZIKV Abs cross-react with
EDIIIs of other flaviviruses, we used SPR to determine Ab
binding affinities for EDIII domains. To avoid avidity effects, the
monomeric EDIII domains were injected over mature and iGL
versions of IgGs coupled to biosensor flow cells. The analytes
included EDIIIs from ZIKV, DENV1, DENV2, DENV3,
DENV4, WNV, and YFV, and the IgG ligands included
Z004mature, Z006mature, Z031mature, Z032mature, Z034mature,
Z035mature, Z036mature, Z004iGL, and Z03XiGL.
Sensorgrams revealed strong binding of both ZIKV and
DENV1 EDIII to all mature IgGs, with low nanomolar or
picomolar equilibrium dissociation constants (KDs) (Fig. 2A,
Table 1, and SI Appendix, Figs. S4A and S5–S7). The KD values
for Z004mature, Z006mature, Z032mature, Z034mature, Z035mature
and Z036mature were all ∼2 to 14× lower for ZIKV EDIII than
DENV1 EDIII, demonstrating stronger binding to ZIKV EDIII.
Z031mature was the only IgG to bind more tightly to DENV1 than
ZIKV EDIII. Mature IgGs showed weak binding to some of the
EDIIIs; specifically, Z004mature, Z006mature, and Z034mature with
DENV2 EDIII, Z004mature with DENV4 EDIII, and all mature
IgGs with WNV EDIII (KDs >100 μM) (Table 1 and SI Ap-
pendix, Figs. S8–S12). Although the binding of Abs to DENV2,
DENV4, and WNV is weak (SI Appendix, Figs. S8A, S10A, and
S11A), it is clearly detectable compared to negative controls that
show no binding (SI Appendix, Figs. S8B, S9, S10B, S11B, and
S12). However, reporter viral particle (RVP)-based neutraliza-
tion assays with a subset of VH3-23/VK1-5 Abs showed mature
Abs neutralize ZIKV and DENV1, but not WNV (SI Appendix,
Fig. S13). Additionally, RVP-based ADE assays showed no
ability of mature Abs to induce ADE of DENV2 or WNV (SI
Appendix, Fig. S14).
As expected, the iGL IgGs bound EDIII with lower affinities
(e.g., low micromolar to high nanomolar KDs for the interactions
of Z004iGL and Z03XiGL with ZIKV and DENV1 EDIII, re-
spectively) than the mature IgGs (Fig. 2B, Table 1, and SI Ap-
pendix, Fig. S4B). The iGL IgGs bound ZIKV EDIII with ∼22 to
83× higher affinity than DENV1 EDIII, similar to the trend
shown by mature IgGs (Fig. 3). The only other EDIIIs that
showed detectable interactions with iGL IgGs were Z03XiGL–
DENV2 EDIII and Z03XiGL–DENV4 EDIII (Table 1 and SI
Appendix, Figs. S8 and S10). While the Z004iGL and Z03XiGL
IgGs neutralized ZIKV RVPs (NT50s [concentration at 50%
neutralization] of 8.8 ng/mL and 0.82 ng/mL, respectively) and
DENV1 RVPs (NT50s: 1,400 ng/mL and 40 ng/mL), these iGL
IgGs also showed ability to induce some ADE of ZIKV and
DENV1 (but not DENV2 or WNV) (SI Appendix, Figs. S13
and S14).
To characterize affinity maturation of anti-ZIKV Abs and the
structural correlates of Ab cross-reactivity, we set up crystalli-
zation screens for all 7 Fabs and for the 31 Fab–EDIII complexes
that exhibited detectable binding interactions (Table 1). Crystals
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were obtained and X-ray structures determined for two com-
plexes: Z004iGL Fab with ZIKV EDIII (3.1 Å resolution) and
Z032mature Fab with WNV EDIII (2.9 Å resolution) (SI Appen-
dix, Table S1).
Comparing iGL and Mature Fab Interactions with Flavivirus EDIIIs.
Crystals of the Z004iGL Fab–ZIKV EDIII complex contained
two Fab–EDIII complexes in the asymmetric unit (root mean
square deviation [rmsd] of 0.37 Å for 279 Cα atoms in the VH-VL
and EDIII domains) (SI Appendix, Table S1). The structure
revealed that Z004iGL binds the same epitope on the EDIII
lateral ridge as Z004mature. Alignment of the EDIII portions of
both complexes revealed similar binding interactions, including
recognition of the EDIII EK amino acid motif (E393-K394) that
is central to the binding epitope in the Z004mature Fab–DENV1
EDIII (PDB ID code 5VIC) and Z006mature–ZIKV EDIII (PDB
ID code 5VIG) crystal structures (Fig. 4 and SI Appendix, Fig.
S15A and Table S2) (28).
To compare the binding interfaces of the iGL and mature Abs
with EDIII, we calculated buried surface areas (BSAs) on the
Fab and EDIII in each complex (Fig. 5). Increased BSA gener-
ally correlates with a larger number of interface residues and a
higher binding affinity (55). As expected from the low affinity of
the Z004iGL Fab interaction with EDIII, less surface area was
buried by EDIII on Z004iGL Fab (∼660 Å2) than on Z004mature
(∼810 Å2) or Z006mature (∼890 Å2) (Fig. 5). The difference in
Fab BSA between Z004iGL and Z004mature was largely accounted
for by interactions with VL rather than VH. Specifically, the VH
BSA was similar for Z004iGL (∼410 Å2) and Z004mature (∼400
Å2), whereas the VL BSA was greater for Z004mature (∼410 Å2)
than Z004iGL (∼250 Å2). There was more EDIII surface area
buried by VH than by VL for all complexes (Fig. 5). Since the
Z004iGL–ZIKV EDIII and Z004mature–DENV1 EDIII structures
do not directly compare iGL and mature Z004 binding to the
same EDIII, we also made a homology model of Z004mature–
ZIKV EDIII binding by threading the sequence of ZIKV EDIII
A
B
Fig. 1. Alignments of VH and VL sequences of mature and iGL versions of Abs isolated from patients exposed to ZIKV. (A) Z004 mature and iGL Ab. (B) Mature
and iGL Z03X Abs. CDR1, CDR2, and CDR3 are orange, blue, and red, respectively. The Kabat numbering scheme was used.
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onto the structure DENV1 EDIII in the Z004mature–DENV1
EDIII structure. The BSA on the Fab (770 Å2) for the Z004mature–
ZIKV EDIII model showed the same trend as Z004mature–DENV1
EDIII: The VH BSA of Z004mature (∼390 Å2) was similar to Z004iGL
(∼410 Å2), whereas the VL BSA was greater for Z004mature (∼380
Å2) than Z004iGL (∼250 Å2) (Fig. 5).
A
B
Fig. 2. SPR binding assays with ZIKV EDIII. IgGs were captured on a protein A biosensor chip, and the indicated concentrations of ZIKV EDIII were injected.
Sensorgrams are indicated in colors representing different injected concentrations. (A) Mature IgGs binding to ZIKV EDIII. Fits to a 1:1 binding model are in
black; since the models very closely fit the data, the models are only slightly visible. The legend shown in the Bottom Left applies to all sensorgrams. Residual
plots for the 1:1 binding model fitting are shown in SI Appendix, Fig. S7A. Two independent experiments were performed; the other set of sensorgrams is
shown in SI Appendix, Fig. S5. (B) iGL IgGs binding to ZIKV EDIII. Fitting curves for equilibrium binding responses are shown in Fig. 3. The y axes show RU. The
legend shown (Right) applies to both sensorgrams.
Table 1. KDs (nM) of mature and iGL Ab binding to EDIIIs determined by SPR
IgG
EDIII
ZIKV DENV1 DENV2 DENV3 DENV4 WNV YFV
Z004mature 0.28 0.47 >100,000 n.b. >100,000 >100,000 n.b.
Z006mature 0.50 1.7 >100,000 n.b. n.b. >100,000 n.b.
Z031mature 3.0 0.33 n.b. n.b. n.b. >100,000 n.b.
Z032mature 0.30 1.1 n.b. n.b. n.b. >100,000 n.b.
Z034mature 0.059 0.80 >100,000 n.b. n.b. >100,000 n.b.
Z035mature 0.78 5.2 n.b. n.b. n.b. >100,000 n.b.
Z036mature 0.29 0.53 n.b. n.b. n.b. >100,000 n.b.
Z004iGL 1,200 >100,000 n.b. n.b. n.b. n.b. n.b.
Z03XiGL 92 2000 >100,000 n.b. >100,000 n.b. n.b.
n.b: No detectable binding at concentrations ≤150 μM.
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Z004iGL showed only 5 residues that interact with the ZIKV
EDIII antigen compared with 10 interacting residues for
Z004mature (with DENV1 EDIII in the crystal structure and with
ZIKV EDIII in the homology model) and 13 residues in
Z006mature Fabs that interact with ZIKV EDIII (SI Appendix,
Fig. S16 A–D and Table S2). The finding of fewer interacting
residues is consistent with the weaker binding of Z004iGL,
demonstrated by SPR (Figs. 2 and 3 and Table 1). Similar to the
trends with differences in BSA, differences in the number of Fab
residues predicted to interact with EDIII was pronounced for
VL: one by Z004iGL VL, four by Z004mature VL (with ZIKV in the
model), five by Z004mature VL (with DENV1), six by Z006mature
VL (with ZIKV) (SI Appendix, Fig. S16 A–D and Table S2).
Among Fab residues that interact with EDIII by either Z004iGL
or Z004mature, we observe that the only residues that differ in
sequence between the iGL and mature version are in the VL
CDRL3: F91VL, Y92VL and V94VL in Z004mature, compared with
Y91VL, N92VL, and Y94VL in Z004iGL (SI Appendix, Figs. S16
and S17A and Table S2). Two of these residues, F91VL and
Y92VL, interact with the ZIKV EDIII EK motif. In contrast, the
only residues that interact with EDIII by both Z004mature and
Z004iGL are in the VH and share the same sequence: S56VH
(CDRH2), Y58VH (framework region [FWR]H3), and E100CVH
(CDRH3). Z006mature Fab also shared one of the same VH
interacting residues: Y58VH (FWRH3) (SI Appendix, Fig. S16
and Table S2).
To further investigate the effects of affinity maturation in the
VH versus the VL domain for high-affinity EDIII binding, we
prepared two Z004 chimeric IgGs for SPR and neutralization
assay analysis: One with mature VH and iGL VL and the other
with iGL VH and mature VL. The SPR sensorgrams for ZIKV
EDIII binding to the Z004 chimeras were fit to a 1:1 binding
model (SI Appendix, Fig. S18) and showed 10-fold higher affinity
binding to the ViGL HC-Vmature LC chimera (KD: 2.5 nM) than to
the Vmature HC-ViGL LC chimera (KD: 29 nM) (SI Appendix, Table
S3). The ViGL HC-Vmature LC sensorgrams appeared similar to
mature VH-VL sensorgrams (slow off-rate), whereas the Vmature
HC-ViGL LC sensorgrams were more similar to the iGL VH-VL
sensorgrams (fast off-rate), consistent with the importance of
light-chain (LC) maturation in the development of high-affinity
recognition of Zika EDIII. Neutralization assays comparing the
two chimeric Abs showed that while both Z004 chimeras can
neutralize ZIKV and DENV1, the ViGL HC-Vmature LC chimera
neutralizes just as potently (NT50: 0.34) as fully mature Z004 IgG
(NT50: 0.55), while Vmature HC-ViGL LC chimera neutralizes with
slightly lower potency (NT50: 1.00) (SI Appendix, Fig. S13).
To assess which residues are important for high-affinity
binding, we first prepared ZIKV EDIII with the EK motif
(central to the binding epitope and involved in several interac-
tions with Z004), mutated to alanines (E393A-K394A) for
binding studies with SPR. Binding of Z004mature IgG to ZIKV
1 10 100 1000 10000 100000 1000000
0
50
100
[EDIII] (nM)
%
 b
ou
nd
EDIII        iGL IgG
ZIKV EDIII          Z004iGL          KD:  1.2 M
DENV1 EDIII          Z004iGL      KD:  >100 M
DENV1 EDIII          Z03XiGL      KD:  2.0 M
ZIKV EDIII          Z03XiGL          KD:  92 nM
Fig. 3. Comparison of qualitative ZIKV and DENV EDIII binding to iGL IgGs.
Normalized Req from the sensorgrams in Fig. 2B and SI Appendix, Fig. S4B are
plotted versus the log of the concentration of the indicated injected proteins
with best fit binding curves to the experimental data points shown as con-
tinuous lines. The SEs of the fit and 95% confidence intervals (CI) of the KDs are
as follows: ZIKV EDIII→ Z03XiGL IgG (KD: 92 nM; SE: 4.9 nM; CI: 79 to 100 nM),
ZIKV EDIII → Z004iGL IgG (KD: 1.2 μM; SE: 61 nM; CI: 1,100 to 1,400 nM), and
DENV1 EDIII → Z03XiGL IgG (KD: 2.0; SE: 100 nM; CI: 1,700 to 2,200 nM). Since
DENV1 EDIII → Z004iGL binding reaction did not reach equilibrium, the KD is
approximated as greater than the highest concentration of analyte injected.
A
B
Fig. 4. Recognition of ZIKV EDIII by Z004 iGL and mature Fabs. Fab–EDIII structures are shown as cartoon representations with Fab VH-VL domains only and
the EK motifs of ZIKV and DENV1 EDIIIs highlighted as sticks (indicated by arrows). (A) Z004iGL Fab–ZIKV EDIII structure. (B) Superimposition of the Z004iGL
Fab–ZIKV EDIII and Z004mature Fab–DENV1 EDIII (PDB 5VIC) structures (28). Structures were superimposed on the EDIII.
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EDIIIAA mutant was nearly abolished with a KD of >>100 μM (SI
Appendix, Fig. S17B and Table S3). To verify that the Z004 VL
residues that interact with EDIII and differ between Z004iGL
and Z004mature (F91VL, Y92VL, and V94VL) are important for
high-affinity binding to ZIKV EDIII, we prepared Z004mature
IgG variants with two or all three residues mutated to alanines.
When the two EK-interacting residues were mutated (Z004mature
IgG: VL F91A-Y92A), we observed 100-fold reduced binding
affinity to ZIKV EDIII (KD: 35 nM). When all three residues
were mutated (Z004mature IgG: VL F91A-Y92A-V94A), we ob-
served 1,000-fold reduced binding affinity (KD: 230 nM) (SI
Appendix, Fig. S17 C and D and Table S3).
Structural Correlates of Weak Ab Cross-Reactivity. We were able to
crystallize a complex of Z032mature Fab bound to WNV EDIII
despite the low affinity of this interaction (KD ≥ 100 μM) (Ta-
ble 1). Perhaps correlating with the low affinity of the complex,
the crystallographic asymmetric unit contained one Fab–WNV
EDIII complex and four unbound Fabs (Fig. 6A and SI Appendix,
Table S1). The four unbound Fabs were similar to each other
(rmsds ranging from 0.22 Å to 0.47 Å for pairwise superimpo-
sitions of 203 to 214 Cα residues in the VH-VL domains) (SI
Appendix, Table S4). WNV EDIII-bound and -unbound Fabs
were also similar (rmsds ranging from 0.35 Å to 0.45 Å for
pairwise superimpositions of 210 to 217 Cα residues in the
VH-VL domains), indicating no major structural changes upon
EDIII binding (SI Appendix, Fig. S19 and Table S4).
The Z032mature Fab–WNV EDIII structure showed that
Z032mature Fab interacts with WNV EDIII at the lateral ridge
epitope recognized by Z004mature, Z006mature, and Z004iGL, al-
though with a low Fab BSA (∼630 Å2) (Figs. 5 and 6 and SI
Appendix, Fig. S14). Similar to Z004iGL, the VH (420 Å
2) con-
tributes more to the total Z032mature Fab BSA than VL (210 Å
2).
The low Fab BSA correlates with fewer interacting residues at
the binding interface: Only eight Z032 Fab residues were found
to interact with six WNV EDIII residues (SI Appendix, Fig. S16
and Table S2). Some Z032mature Fab interacting residues were
also involved in interactions in other Fab–EDIII structures:
S56VH (in Z004iGL and Z004mature), Y58VH (FWR3) (in
Z004iGL, Z004mature, and Z006mature), R96VH (CDRH3) (in
Z004mature and Z006mature), E100CVH (CDRH3) (in Z004iGL
and Z004mature), Y91VL (in Z006mature), and Y94VL (in Z004iGL)
(SI Appendix, Fig. S16 and Table S2). This suggests that these
residues contribute to enhanced cross-reactivity of anti-ZIKV
VH3-23/VK-15 Abs.
Discussion
Understanding the structural basis of Ab recognition of ZIKV
and other flavivirus antigens informs considerations and pre-
cautions for vaccine design to elicit EDIII-specific Abs. Here we
conducted binding and structural studies comparing interactions
A
B
C
Fig. 5. Comparison of Fab–EDIII binding interfaces. Surface representations of the (A) EDIII epitopes contacted by Fabs and (B) Fab binding epitopes con-
tacted by EDIII in the Z004iGL Fab–ZIKV EDIII (PDB ID code 6UTA), Z004mature Fab–ZIKV EDIII homology model, Z004mature Fab–DENV1 EDIII (PDB ID code 5VIC),
Z006mature Fab–ZIKV EDIII (PDB ID code 5VIG), and Z032mature Fab–WNV EDIII (PDB ID code 6UTE) structures (left to right) (28). The Z004mature Fab–ZIKV EDIII
homology model was made by threading the sequence of ZIKV EDIII onto the structure DENV1 EDIII in the Z004mature–DENV1 EDIII structure. Binding epitopes
are shown as surfaces over cartoon representations. CDRs are colored as indicated (Right). (C) Quantification of BSA (Å2 and percentage of total surface area)
and number of interface residues buried on the entire EDIII (Left) and VH and VL of the Fab (Right) based on the interfaces mapped in A and B. The column
labeled total buried surface area for Fabs includes the sum of BSA for the VH and VL.
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of mature and iGL VH3-23/VK1-5 Abs isolated from ZIKV-
exposed donors with a panel of flavivirus EDIII domains to
provide insight into the affinity maturation process of this class
of potently neutralizing ZIKV Abs. In addition to revealing in-
teractions critical for potent binding to ZIKV, we also identified
weaker interactions that may contribute to cross-reactivity and
potentially ADE.
By comparing mature and iGL VH3-23/VK1-5 Ab binding to
EDIIIs, we identified the mutations introduced through somatic
hypermutation that facilitate tight binding of the Z004 Ab to
ZIKV. As expected, a crystal structure of a Z004iGL–EDIII
complex showed fewer Fab residues that interact with EDIII
than observed for EDIII complexes including mature Fabs, such
as Z004mature, Z006mature, and Z032mature (28). In a direct com-
parison of the Z004mature–DENV1 EDIII structure and
Z004mature–ZIKV EDIII homology model with the Z004iGL–
ZIKV EDIII structure, the only three Fab residues involved in
interactions with EDIII that differed in sequence between
Z004mature and Z004iGL are in VL. In contrast, the three inter-
acting residues that are shared by both Z004mature and Z004iGL
are in VH. This suggests that affinity maturation of VL CDRL3
may be particularly important for higher affinity binding to
EDIII. This is further supported by the finding that the increased
BSA on Z004mature compared to Z004iGL was largely accounted
for by an increase in the VL BSA. Comparison of the binding
affinities and neutralization potencies of Z004 mature/iGL chi-
meras also suggests the importance of VL maturation for EDIII
recognition.
Through investigation of the effects of site-directed mutations
in Z004mature IgG and ZIKV EDIII on binding, we showed that
interactions with the EDIII EK motif are critical for high-affinity
binding. While both VH and VL residues interact with the EK
motif, the only EDIII-interacting residues that differ between
Z004mature and Z004iGL are in VL (F91, Y92, and V94). The
reduced binding affinity when these residues are mutated to al-
anines supports that affinity maturation of the VL is important
for high-affinity binding.
The importance of VL somatic hypermutation was also ob-
served in a previous longitudinal analysis of a ZIKV-infected
patient to trace the lineage of ZK2B10, a protective VH1-8/
VL1-47 Ab against ZIKV that binds a different part of the EDIII
lateral ridge (56). Two residues in the VL1-47 germline-coded λ
VL, N31 (CDRL1) and S91 (CDRL3), were shown to be nec-
essary and sufficient for functional maturation of the VH1-8/
VL1-47 Ab lineage to achieve potent ZIKV neutralization. They
observed low somatic hypermutation in germline-like somatic
variants of VH, concluding that restricted VH gene segment us-
age, rather than somatic hypermutation in the VH domain, was
important to achieve high affinity and potency. While ZK2B10 is
derived from different germline genes and binds a different part
of the EDIII lateral ridge than the VH3-23/VK1-5 Abs studied
here, we observed a similar trend for the VH3-23/VK1-5 Ab
Z004: Affinity maturation of VL was important for strong bind-
ing and neutralization, while VH interactions were restricted to
residues already present in the germline gene.
Through assessment of VH3-23/VK1-5 Ab binding to a panel
of flavivirus EDIIIs using SPR, the Abs tightly bound ZIKV and
DENV1 and weakly bound DENV2, DENV4, and WNV EDIII,
indicating a potential for cross-reactivity. Although this class of
mature Abs was shown to neutralize DENV1 in addition to
ZIKV (28), the ability of iGL Abs to bind DENV1 EDIII as well
as the apparent weak binding of both mature and iGL Abs to
other flaviviruses suggests the possibility of ADE upon sub-
sequent infection with a different flavivirus in humans. The EK
motif, which is only present in ZIKV and DENV1 EDIII, likely
contributes to initial recognition by germline Abs that leads to
A
B
Fig. 6. Cross-reactive recognition of WNV EDIII by Z032mature Fab. Fab–EDIII complex structures are shown as cartoon representations with Fab VH-VL domains
only and the EQ or EK motifs of WNV and DENV1 EDIIIs highlighted as sticks. (A) Z032mature Fab–WNV EDIII structure. (B) Superimposition of the Z032mature
Fab–WNV EDIII and Z004mature Fab–DENV1 EDIII (PDB 5VIC) structures (28). Structures were superimposed on the EDIII domains.
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the tighter binding and neutralization of these two flaviviruses by
VH3-23/VK1-5 Abs. The importance of E393 in the EK motif
for neutralization of ZIKV strains was also previously described
for the VH3-23/VK1-5 Ab ZIKV-116 (57). In contrast to ZIKV
and DENV1, the lateral ridges of DENV2, DENV4, and WNV
EDIIIs all contain motifs other than EK, yet still showed weak
binding to at least one mature or iGL Ab by SPR. This suggests
the interactions that contribute to cross-reactive binding of Abs
to these flaviviruses are different from, or only partially overlap
with, the interactions that contribute to high affinity and neu-
tralizing binding to ZIKV and DENV1 EDIIIs. Apart from
DENV1, WNV EDIII was the only flavivirus for which all seven
mature VH3-23/VK1-5 Abs showed cross-reactivity (Table 1).
Given that binding to DENV2, DENV4, and WNV EDIIIs is
weak (KD ≥ 100 μM), it is unclear whether this cross-reactivity
could facilitate ADE of these flaviviruses upon infection. How-
ever, our RVP-based assays showing no ADE for DENV2 or
WNV infection suggests this is of low concern. The potential for
cross-reactivity of other Abs with ZIKV and WNV EDIII was
shown in studies demonstrating that previous exposure to WNV
enhances subsequent ZIKV infection in mice, although immu-
nodominant DII-specific fusion loop Abs might explain this
in vivo enhancement (41).
The crystal structure of Z032mature Fab complexed with WNV
EDIII provides an example of the structural basis of cross-
reactive recognition. This structure shows that the Z03X Abs
bind the same lateral ridge epitope as other VH3-23/VK1-5 Abs
(28). A few Z032mature Fab-interacting residues (S56VH
[CDRH2], Y58VH [FWRH3], R96VH [CDRH3], E100CVH
[CDRH3], Y91VL [CDRL3], and Y94VL [CDRL3]) are also in-
volved in at least one other interaction in the Z004iGL,
Z004mature, and Z006mature complexes with EDIII domains. This
suggests these residues, including the one in a conserved FWR
(Y58VH), may contribute to cross-reactivity of VH3-23/VK-15
Abs, potentially even precursor germline versions, with different
flaviviruses. These residues are present in iGL sequences, sug-
gesting that residues that contribute to cross-reactivity may al-
ready be present prior to affinity maturation. The weak, cross-
reactive binding of Z004iGL to DENV1 EDIII and of Z03XiGL to
DENV1, DENV2, and DENV4 further supports this suggestion.
Five of the eight Z032mature Fab residues predicted to bind WNV
EDIII are in the VH, suggesting the VH may contribute more to
weak, cross-reactive binding, whereas somatic hypermutation in
the VL may contribute more to tight binding of mature VH3-23/
VK1-5 Abs to ZIKV.
Comparison of the structures of bound and unbound
Z032mature Fabs indicated the VH3-23/VK1-5 class of Abs does
not require major conformational changes for binding. Super-
imposition of the bound and unbound Z032mature VH-VL
revealed a low calculated rmsd and no major differences in the
backbone structure, suggesting that conformations were pre-
formed prior to binding. This suggests that VH3-23/VK1-5 ma-
ture Abs use a lock-and-key mode of binding, involving minimal
conformational changes between the bound and unbound states
of antigen and Ab (58–60).
Germline versions of VH3-23/VK1-5 ZIKV-neutralizing Abs
showed detectable binding to ZIKV and DENV1 EDIII in the
nanomolar and low micromolar range. This was also previously
observed for the germline version of the VH3-23/VK1-5 Ab
ZIKV-116, which bound (KDs of 48.9 nm-10 μM) and neutral-
ized ZIKV and DENV1 strains (57). This ability of germline
versions of VH3-23/VK1-5 Abs to bind ZIKV contrasts with
germline-reverted forms of most broadly neutralizing Abs
against HIV-1, which generally do not bind HIV-1 envelope (61).
The ability of germline versions of neutralizing Abs to bind an-
tigens is of particular interest for vaccine design, as this suggests
immunogens may effectively elicit precursors of the desired Ab
class, which could then mature into neutralizing Abs. Initial
studies of the potential of ZIKV EDIII to serve as a safe and
effective immunogen are underway, and indicate potential to
elicit a specific and potent neutralizing Ab response to ZIKV in
mice (62–64).
Increased understanding of the differences in the interactions
that contribute to neutralization versus cross-reactivity leading to
ADE may enable strategic immunogen design. The in vitro
ability of germline and mature (65) VH3-23/VK1-5 Abs to in-
duce some ADE for ZIKV and DENV1, but not for DENV2 or
WNV, suggests there may be minimal risk of ADE due to weak
cross-reactivity for this class of Abs. While this is not indicative
of in vivo ability to enhance infection, there may be concern that
Ab titers falling below neutralizing levels may be a risk for ADE.
These findings indicate the importance of examining the cross-
reactivity and ADE-potential of other anti-ZIKV classes of Abs
under consideration for vaccine design or passive delivery. Un-
derstanding which residues contribute to cross-reactivity versus
potent neutralization may also inform the necessity of modifying
passively delivered Abs to reduce cross-reactivity and prevent
ADE by introducing Fc of mutations that prevent FcγR binding.
Materials and Methods
Design of iGL Versions of Abs against ZIKV. Sequences of iGL versions of anti-
ZIKV Abs are based on V, D, and joining J gene segment assignments from
IgBlast (28, 54). All mature IGHV3-23/IGKV1-5 Ab sequences from donors
MEX 18 and BRA 112 were considered for design of the Z004 and Z03X iGLs,
respectively. CDR1 and CDR2 of the iGLs were based on the V gene segment
assignment of the mature sequences, specifically IGHV3-23 for the heavy
chain (HC) and IGKV1-5 for the LC. The CDRH3 of the iGL was based on a
consensus of the V, D, and J gene segment assignments for the mature HC
sequences, and CDRL3 of the iGL was based on a consensus of V and J gene
segment assignments for the mature LC sequences (SI Appendix, Figs. S1–S3).
Protein Expression. Abs were produced as previously described (28, 66).
Briefly, Z006mature, Z031mature, Z032mature, Z034mature, Z035mature, Z036mature,
and Z03XiGL IgGs were expressed by transient transfection of HEK293-6E cells
with equal amounts of Ig HC and LC expression vectors. After 7 d, IgGs were
purified from supernatants using Protein G Sepharose 4 Fast Flow (GE
Healthcare). Z004mature, Z004iGL, and N6 IgGs were expressed by transient
transfection and purified from supernatants using a HiTrap MabSelect col-
umn (GE Healthcare) and size-exclusion chromatography (SEC) using a
Superdex 200 column (GE Healthcare) in 20 mM Tris pH 8.0, 150 mM NaCl.
Fabs with C-terminal His-tags were produced by transient transfection of
Expi293F cells with equal amounts of HC and LC expression vectors. The Fabs
were purified from supernatants with Ni-NTA affinity chromatography and
SEC with a Superdex 200 column in 20 mM Tris, 150 mM NaCl.
Flavivirus EDIIIs were expressed in Escherichia coli and purified from in-
clusion bodies as previously described (28, 36, 67). Briefly, EDIII genes from
ZIKV (H/PF/2013 strain, GenBank KJ776791), DENV1 (45AZ5 strain, National
Center for Biotechnology Information [NCBI] reference NC_001477), DENV2
(NCBI reference NC_001474), DENV3 (NCBI reference NC_001475.2), DENV4
(NCBI reference NC_002640.1), YFV (Asibi strain, GenBank KF769016), and
WNV (GenBank KX547539.1) in pET21 expression plasmids were transformed
into BL21 (DE3) competent cells and cultures were grown in LB with car-
benicillin at 37 °C. Expression was induced with isopropyl-β-D-thiogalacto-
pyranoside at an OD of ∼0.6, and the culture was harvested after 4 h and
stored overnight at −20 °C. The pellet was resuspended in 20 mM Tris pH 8.0,
150 mM NaCl, cells were lysed and centrifuged at 21,000 × g for 30 min, and
the pellet was resuspended in 6 M guanidine hydrochloride, 100 mM Tris·HCl
pH 8.0. This suspension was centrifuged again at 21,000 × g for 30 min, and
then 20 mM β-mercaptoethanol was added to the supernatant. EDIII in the
supernatant was refolded by dropwise, rapid dilution into 400 mM L-argi-
nine, 100 mM Tris-base pH 8.0, 2 mM EDTA, 5 mM reduced glutathione,
0.5 mM oxidized glutathione, and 10% glycerol at 4 °C. The protein was
then concentrated and purified by SEC with a Superdex 75 column (GE
Healthcare) in 20 mM Tris pH 8.0, 150 mM NaCl, 0.02% NaN3.
SPR Binding Assays. SPR experiments were performed using a Biacore T200
instrument (GE Healthcare). Binding assays were done by flowing EDIII
analytes over IgG ligands bound to a protein A-coupled biosensor chip in 0.2-
μm–filtered HBS-EP+ running buffer. The protein A-coupled chip was pre-
pared from a CM5 chip (GE Healthcare) by coupling 1 μM His-tagged Protein
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A at pH 4.5 to each flow cell to a final density of ∼3,000 response units (RUs).
IgGs were then injected onto each flow cell at 50 nM. An irrelevant HIV-1
Ab, N6 (68), was used as a control on a reference flow cell. To remove IgGs
from the chip between runs, a solution of 10 mM glycine 50% (vol/vol) pH
1.5/pH 2.5, 1 M guanidine hydrochloride was applied.
For interactions with measurable on- and off-rates, kinetic constants were
derived from sensorgram data using global fitting of the association and
dissociation phases of binding curves in the working set using Biacore T200
Evaluation Software (GE Healthcare). The sensorgrams were fit to a binding
model that assumed a single class of noninteracting binding sites in a 1:1
binding interaction. KD values were derived as KD = kd/ka, the ratio of the
association (ka) and dissociation (kd) constants. For interactions with fast on-
and off-rates, KD values were derived by nonlinear regression analysis of
plots of Req (the equilibrium binding response) versus the log of the injected
protein concentration. Data were fit to a 1:1 binding model, and each KD
was determined as the concentration at which half-maximal binding was
observed. If a saturated binding response was not achieved at the highest
injected concentration of analyte, we approximated the saturated response
as the highest Req achieved.
For SPR runs used to determine KD values, the EDIIIs for ZIKV, DENV1-4,
WNV, and YFV were dialyzed into HBS-EP+ running buffer using a
Slide-A-Lyzer MINI Dialysis Device with 3,500 Da molecular mass cutoff
(ThermoFisher) to minimize refractive index changes between the associa-
tion and dissociation phases. We used concentrations of ZIKV and DENV1
EDIII ranging from 0.04 to 10 nM in a threefold dilution series flowed
over immobilized mature IgG, and concentrations of ZIKV, DENV1, and
ZIKVAA mutant EDIIIs ranging from 2.3 nM to 150 μM in a fourfold dilution
series flowed over immobilized iGL IgGs or Z004mature IgG and the control
IgG. Concentrations of DENV2, DENV3, DENV4, WNV, and YFV EDIIIs from
2.3 nM to 150 μM in a fourfold dilution series were flowed over immobilized
mature and iGL IgGs. Concentrations of ZIKV EDIII ranging from 0.036 nM to
150 μM in a fourfold dilution series were flowed over immobilized Z004 iGL/
mature chimeric IgGs in two independent experiments. Concentrations of
ZIKV EDIII ranging from 0.036 nM to 37.5 μM in a fourfold dilution series
were flowed over immobilized Z004 IgG VL site-directed mutants. The injection
flow rate was 10 μL/min over 3 min and the dissociation time was 2 min. For
repeated SPR runs for ZIKV and DENV1 EDIII flowed over mature IgGs, con-
centrations of EDIII from 1.4 to 1,000 nM in a threefold dilution series were
injected at a flow rate of 30 μL/min over 1 min and a dissociation time of 5 min
(SI Appendix, Figs. S5 and S6). KDs for mature IgG binding to ZIKV EDIII and
DENV1 EDIIIs were calculated as the average of two independent experiments.
Crystallization Trials. For the Z004iGL Fab–ZIKV EDIII complex, Fabs and EDIII
were incubated at a 1:1.8 molar ratio for 3 d and then purified by SEC on
Superdex 200 10/300 Increase column (GE Healthcare). For the Z032mature
Fab–WNV EDIII complex, Fabs and EDIII were incubated at a 1:1 molar ratio
for 3 d. Crystallization trials were set up at ∼5 mg/mL (Z004iGL Fab–ZIKV
EDIII) and ∼10 mg/mL (Z032mature Fab–WNV EDIII) in sitting-drop plates with
a Mosquito microcrystallization robot and stored at room temperature.
Crystals were cryoprotected with 25% glycerol. Crystallization conditions
corresponding to determined structures include 1% (wt/vol) tryptone,
0.001 M sodium azide, 0.05 M Hepes sodium pH 7.0, 20% (wt/vol) poly-
ethylene glycol 3350 (Z004iGL Fab–ZIKV EDIII) and 0.2 M sodium bromide,
20% (wt/vol) polyethylene glycol 3350 (Z032mature Fab–WNV EDIII).
X-Ray Structure Determinations. X-ray data for the Z004iGL Fab–ZIKV EDIII
structure were collected at the Stanford Synchrotron Radiation Lightsource.
Data for the Z032mature Fab–WNV EDIII complex were collected at the Ad-
vanced Photon Source, Argonne, IL, using the GM/CA 23-ID-D beamline.
Z004iGL Fab–ZIKV EDIII diffraction data were processed using the XDS
package (69), and Z032mature Fab–WNV EDIII complex data were processed
using iMosflm (70). Data were scaled using Pointless and Aimless (71, 72).
Structures were solved by molecular replacement (MR) using Phaser-MR
(73). For the Z004iGL Fab–ZIKV EDIII structure, the structure was first de-
termined at 3.3 Å using Z004mature Fab–DENV1 EDIII (PDB ID code 5VIC) as
the initial search model (28). This gave a partial solution with two Z004mature
Fab–DENV1 EDIII molecules in the asymmetric unit, with one of the Fabs
containing an incorrectly placed constant (CHCL) domain. This CHCL domain
was removed and MR was repeated using the initial partial solution and one
Z004mature CHCL as search models. The structure was then determined at 3.1
Å using a similar method, except the Fab with the incorrectly placed CHCL
domain was completely removed and MR was repeated using the initial
partial solution and the corresponding Z004mature Fab–DENV1 EDIII from the
3.3 Å structure as a search model. For the Z032mature Fab–WNV EDIII com-
plex, Z006mature VHVL and Z006mature CHCL (PDB ID code 5VIG) domains were
used as the initial search models (28), which produced a partial solution with
four VHVL and four CHCL. MR was repeated using this partial solution and
WNV EDIII (PDB ID code 1ZTX) as search models (33). This generated a partial
solution with one WNV EDIII placed correctly and three placed incorrectly, so
all molecules were removed except for one Fab bound to WNV EDIII. For this
Fab–EDIII partial solution, Fab residues were mutated to match the
Z032mature sequence, and then to generate Z032mature Fab, Z032mature VHVL,
and Z032mature CHCL search models. MR was repeated using the Z032mature
Fab–WNV EDIII partial solution and Z032mature VHVL and CHCL as search
models. This gave a partial solution with two unbound Fabs and one EDIII-
bound Fab correctly placed; again, incorrectly placed molecules were re-
moved. MR was repeated with this partial solution and Z032mature Fab as a
search model. This gave a partial solution with four correctly placed Fabs,
one EDIII-bound and three unbound. MR was repeated with this partial
solution and an additional Z032mature Fab as search models, resulting in the
final structure with four unbound and one EDIII-bound Fab. Protein models
were refined with phenix.refine using torsion angle refinement, group B
factors, and noncrystallography symmetry restraints (74). PDB ID codes and
X-ray data collection and refinement statistics are in SI Appendix, Table S1.
Figures were prepared and rmsds of superimposed C⍺ atoms were cal-
culated using Pymol (75). A Z004 Fab–Zika EDIII homology model was cre-
ated using SWISS-MODEL (76). A control for the homology model was
prepared by threading ZIKV EDIII onto DENV1 EDIII in the Z021 Fab–DENV1
EDIII structure (PDB ID code 6DFJ); comparison of VHVL–EDIIIs from the Z021
Fab–ZIKV EDIII homology model and the known Z021 Fab–ZIKV EDIII struc-
ture (PDB ID code 6DFI) resulted in an rmsd of 0.28 for 239 C⍺ atoms (29).
Fab–EDIII binding interfaces were mapped as residues within 4 Å in Pymol.
BSAs (calculated using a 1.4 Å probe) and the contact residues at Fab–EDIII
interfaces (calculated using a distance of <3.89 Å and an A-D-H angle >90°
for H-bonds and a distance <4 Å for salt bridges) were determined with
PDBePISA (77).
Plasmid Construction. pWNV/TX02/CprME was generated by assembly PCR.
Using pZIKV/HPF/CprME [obtained from Ted Pierson, Viral Pathogenesis
Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda,
MD (28)] as template and oligos RU-O-24611 (5′- CTTGACCGACAATTGCAT
GAAG) and RU-O-24620 (5′- CCTCCTGGTTTCTTAGACATAGCCTGCTTTTTTGTA
CAAAC), the CMV promoter region linked to the beginning of the WNV
capsid protein was amplified. The WNV CprME region with upstream over-
lap with the CMV promoter was amplified using Oligos RU-O-24619 (5′- GTT
TGTACAAAAAAGCAGGCTATGTCTAAGAAACCAGGAGG) and RU-O-24621
(5′- TTCGAACCGCGGCTGGGTCCTATTAAGCGTGCACGTTCACGGAGAG) and a
full-length WNV strain TX02 infectious clone [obtained from Ilya Frolov,
Department of Microbiology, University of Alabama at Birmingham, Bir-
mingham, AL (78)] as a template. The two fragments were assembled by PCR
using oligos RU-O-24611 and RU-O-24621, and the product was digested
with SnaBI and SacII and cloned into similarly digested pZIKV/HPF/CprME. All
PCR-derived DNA regions were verified by sequencing.
RVP Production. RVPs were generated as previously described (28) by
cotransfection of two plasmids: A luciferase-expressing WNV replicon plas-
mid (pWNVII-Rep-REN-IB, obtained from Ted Pierson) and a C-prM-E ex-
pression plasmid encoding structural proteins of ZIKV strain HPF with the
PRVABC59 E protein (pZIKV/HPF/CprM*PRVABC59E*) (79), DENV1 strain WP
(pDENV1/WP/CprME, obtained from Ted Pierson), DENV2 strain 16681
(pDENV2/16681/CprME, obtained from Ted Pierson), or WNV strain TX02
(pWNV/TX02/CprME). Lenti-X 293T cells were seeded at 5 × 105 cells per well
in collagen-coated six-well plates 1 d before DNA transfection. One micro-
gram of pWNVII-Rep-REN-IB (WNV replicon expression construct) and 3 μg of
the flavivirus CprME expression construct were cotransfected with Lip-
ofectamine 2000 (Invitrogen). After incubation at 37 °C for 4 to 5 h, media
(containing lipid–DNA complexes) was removed and replaced with Dulbec-
co’s modified Eagle’s medium (DMEM) containing 20 mM Hepes, 3% fetal
bovine serum (FBS). Cells were then incubated at 34 °C for 48 to 72 h before
supernatant (containing RVPs) was harvested, filtered through a 0.22-μm
filter, and frozen at −80 °C.
RVP-Based Neutralization Assays. Antibodies were diluted in triplicate in
Medium-199 with 17% BSA, 1% P/S (BA-1 diluent) to 40 μg/mL and then
serially diluted in BA-1 diluent using fivefold dilutions. RVPs were diluted in
OPTI-MEM to a concentration that results in ∼1 × 106 relative light units
(RLU) per 25 μL (determined based on a titration of the harvested RVPs on
Huh-7.5 cells). Serially diluted antibodies were mixed with equal volumes of
RVPs and incubated for 1 h at 37 °C. Fifty microliters of RVP–Ab complex was
added to Huh-7.5 cells seeded in 96-well half-area plates at 7.5 × 103 cells per
Esswein et al. PNAS | May 5, 2020 | vol. 117 | no. 18 | 9873
BI
O
CH
EM
IS
TR
Y
D
ow
nl
oa
de
d 
at
 C
al
ifo
rn
ia
 In
st
itu
te
 o
f T
ec
hn
ol
og
y 
on
 M
ay
 5
, 2
02
0 
well in 50 μL the day prior. After incubation at 37 °C for 24 h, media was
removed, cells were lysed in 35 μL 1× Lysis Buffer, and 20 μL was used for
Renilla luciferase measurement on a FLUOstar Omega luminometer (BMG
LabTech) using the Renilla Luciferase Assay System (Promega). Luciferase
activity, measured as RLUs, was normalized as the percentage of luciferase
activity relative to activity from RVPs incubated without Ab. Experiments
were repeated twice and plotted on the same graph. The N6 Ab (negative
control) was assessed at 10 μg/mL final concentration in the well. IC50 values
(the Ab concentration that resulted in 50% inhibition) were determined by
nonlinear regression fitting of the curve in GraphPad Prism.
ADE Assays. Antibodies were diluted in triplicate in BA-1 diluent to 40 μg/mL
and then serially diluted by threefold dilutions. RVPs were diluted in OPTI-
MEM with a goal of achieving ∼1 × 106 Huh-7.5 cell RLU per 12.5 μL (de-
termined based on a titration of the harvested RVPs on Huh-7.5 cells in the
absence of antibody). For some RVPs this goal was not attainable and lower
RLU were used. Serially diluted antibodies were mixed with equal volumes
of RVPs, and incubated for 1 h at 37 °C. Twenty-five microliters of RVP-Ab
complex was added to K562 cells seeded the prior day in poly-L-lysine–
coated 96-well half-area plates at 5.0 × 103 cells per well in 25 μL of DMEM
containing 10% FBS and 1× nonessential amino acids solution (NEAA). Every
plate included a no antibody control, an N6 negative control, and Z004 wild-
type antibody (10 ng/mL final concentration) with ZIKV RVPs as a positive
control. Each plate also included Huh-7.5 cells seeded the day prior at 7.5 ×
103 cells per well in 50 μL to serve as a positive control for RVP activity. After
incubation at 37 °C for 24 h, media was removed, cells were lysed in 35 μL 1×
Lysis Buffer, and 20 μL was used for Renilla luciferase measurement on a
FLUOstar Omega luminometer (BMG LabTech) using the Renilla Luciferase
Assay System (Promega). Luciferase activity, measured as RLUs, was nor-
malized to respective RVP luciferase activity determined on fully permissive
Huh-7.5 cells (positive control). Experiments were repeated twice and plot-
ted on the same graph. The HIV-1 Ab N6 (negative control) and cross-
reactive Ab Z015mature (WNV positive control) were assessed at the highest
concentration (10 μg/mL). Z004mature Ab (positive control) (65) was assessed
at 0.01 μg/mL, a concentration known to show ADE for ZIKV.
Data Availability. Crystallographic coordinates for structures Z004iGL Fab–
ZIKV EDIII and Z032mature Fab–WNV EDIII are available from the Protein Data
Bank under ID codes 6UTA and 6UTE.
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